The value of a biomarker-defined cohort doesn’t end at trial completion — and a health plan’s obligation to members with hereditary findings doesn’t end at diagnosis. Genetic Alerts maintains your relationship with that population automatically, notifying patients and providers when classifications change, new evidence emerges, or new indications become available. For pharmaceutical and payer organizations alike, this is the infrastructure that turns a one-time interaction into a persistent, updatable patient relationship.